Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 September 2005

Systemic Lupus Erythematosus (SLE) in Italy: an Italian prevalence study basedon a two-step strategy in an area of Florence (Scandicci-Le Signe).

Maurizio Benucci, Angela Del Rosso, Francesca Li Gobbi, Mariangela Manfredi, Marco Matucci Cerinic, Carlo Salvarani

Med Sci Monit 2005; 11(9): CR420-425 :: ID: 428449

Abstract

Background: The goal was to ascertain the prevalence of SLE in the populationover18 years of age in the Scandicci-Le Signe area of Florence, Italy, based on the records of generalpractitioners (GPs). Material/Methods: Twenty GPs screened 32,521 patients by administering the LupusScreening Questionnaire (LQS) and found 30 patients with suspected or definite diagnosis of SLE. To confirmthe diagnoses the patients were referred to a rheumatologist who conducted routine examinations and assessedantinuclear antibodies and SLE activity (ECLAM score). Results: Total population >18 years of age inthe three municipalities was 71,204 persons, with 42,474 in Scandicci, 15,368 in Lastra a Signa, and13,362 in Signa. In 23/30 patients diagnosed with SLE the diagnosis was confirmed. Eleven of the 23 SLEpatients were from Scandicci and 6 each from Lastra a Signa and Signa. An overall estimated prevalenceof SLE of 71/100,000 (1/1408; 95% CI=49, 92) was found in the total population of the three municipalities.Scandicci (95% CI=42, 121) had a rate of 81/100.000, while Lastra a Signa (95% CI=32, 92) and Signa (95%CI=36, 94) had estimated rates of 62/100,000 and 65/100,000, respectively. Medium ECLAM score was 4.68+/-1.81SD. Conclusions: This is the first epidemiological study on SLE prevalence in Italy. The prevalence andpoint prevalence are similar to other European studies. The LQS was also confirmed as an easy and reliabletool to assess SLE diagnosis in the Italian population.

Keywords: Family Practice, Italy - epidemiology, Lupus Erythematosus, Systemic - epidemiology, Mass Screening, Questionnaires, Rheumatology

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750